TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma
Jin K, Xu J, Su X, Xu Z, Li B, Liu G, Liu H, Wang Y, Zhu Y, Xu L, Zhang W, Liu Z, Wang Z, Chang Y, Xu J. TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma. The Journal Of Pathology 2024, 263: 139-149. PMID: 38380548, DOI: 10.1002/path.6266.Peer-Reviewed Original ResearchPD-1/PD-L1TP53 mutationsOverall survivalUrothelial carcinomaGenetic alterationsClinical significance of TP53 mutationsPD-1/PD-L1 blockade therapyCD8<sup>+</sup> T cell infiltrationIncreased CD8<sup>+</sup> T cell infiltrationElevated tumor mutation burdenSignificance of TP53 mutationsPD-1/PD-L1 blockadeTP53 disruptive mutationsInflamed tumor microenvironmentPlatinum-based chemotherapyT cell infiltrationTumor immune microenvironmentTumor mutational burdenWild-type TP53P53 protein functionTP53 mutation statusSensitive to immunotherapyHeterogeneous clinical outcomesPoorer overall survivalImprove risk stratificationPOLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Xu J, Wang Z, Liu H, Zhang W. POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1. Cancer Medicine 2024, 13: e6962. PMID: 38457207, PMCID: PMC10922026, DOI: 10.1002/cam4.6962.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerProgrammed cell death ligand 1Immune checkpoint blockadeTumor mutational burdenImmune microenvironmentZhongshan HospitalBladder cancerInfiltration of immune effector cellsEfficacy of immune checkpoint blockadePOLQ expressionCell death ligand 1High tumor mutational burdenChromosomal instabilityActive tumor immune microenvironmentAntitumor immune microenvironmentDeath-ligand 1Efficacy of immunotherapyPlatinum-based chemotherapyTumor immune microenvironmentSensitivity to chemotherapyImmune effector cellsProduction of neoantigensIMvigor210 cohortCheckpoint blockadePD-L1